• {%brandMenuItems%}
    • {%itemName%} {%arrowSpan%}
        {%subBrandMenuItems%}
    • {%itemName%} {%arrowSpan%}
        {%productMenuItems%}
    • {%selfProduct%}
      • {%languages%}
    • This website is for UK Healthcare Professionals only

      ANKYLOSING SPONDYLITIS

      RINVOQ, the first ever once-daily oral JAK inhibitor for the treatment of active AS, PsA and RA1

       

      Improvement in ASAS40 from as early as Week 2 and maintained to Week 64, with significantly more patients treated with RINVOQ 15mg achieving ASAS40 at Week 14 vs placebo.

      Improvement in ASDAS inactive disease rates vs placebo at Week 14.1-3

      Significant improvement in signs of inflammation, as measured by SPARCC-MRI of Spine vs placebo at Week 14. 

      Improvements in BASFI as well as patient-reported back pain, peripheral pain and swelling and nocturnal back pain seen at Week 14.1,2

      The safety profile of RINVOQ in AS was consistent with previously reported results in Rheumatoid Arthritis and no new significant safety signals were identified.1-5

      RINVOQ AS Overview

      I want to find out more about RINVOQ

      I want to receive more information about RINVOQ

      References

      1. RINVOQ (upadacitinib) SmPC.
      2. van der Heijde D, et al. Lancet 2019;394:2108-2117.
      3. Deodhar A, et al. Arthritis Rheumatol. 2020;72(suppl. 10):2023.
      4. McInnes IB, et al. EULAR E-congress 2020;LB0001.
      5. Cohen SB, et al. Arthritis Rheumatol. 2019; 71 (suppl 10):509.

      UK-UPAD-210348. Date of preparation: November 2021

      Adverse events should be reported. Reporting forms and information can be found at yellowcard.mhra.gov.uk.
      Adverse events should also be reported to AbbVie on GBPV@abbvie.com